Eight medicines have been backed for approval by the European Medicines Agency’s Committee for Medicinal Products for Human Use, including new therapies to treat hepatitis C, multiple sclerosis and cancer.
26th June 2017
Portola Pharmaceuticals’ BevyxXa has been cleared by the US Food and Drug Administration for preventing blood clots in hospitalised patients.
26th June 2017
European regulators have validated the marketing authorisation application for Shire’s experimental von Willebrand Disease therapy Veyvondi.
26th June 2017
Roche has presented a new batch of data showing that its experimental bispecific monoclonal antibody emicizumab significantly reduced bleeds in patients with haemophilia A and inhibitors to factor VIII.
26th June 2017
Astellas UK’s membership of the Association of the British Pharmaceutical Industry has been suspended for a further 12 months because of a number of “serious breaches” of the Code of Practice.
23rd June 2017
AstraZeneca’s Daxas is now likely to be routinely available on the NHS to patients with chronic obstructive pulmonary disease (COPD), after new evidence helped persuade cost regulators that the drug is value for money in this setting.
23rd June 2017
US regulators have approved CSL Behring’s Haegarda, the first C1 esterase inhibitor for subcutaneous administration to prevent hereditary angioedema (HAE) attacks in adolescent and adults
23rd June 2017
Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation.
23rd June 2017
NHS England is again issuing a call for the world’s “best healthcare innovations” to improve frontline patient care in a further round of the NHS Innovation Accelerator programme.
23rd June 2017
If the answer is yes, take the first step toward getting your hands on the coveted Pharma by entering your Commercial Cross Functional Team into Marketer of the Year, today!
22nd June 2017
Seize the opportunity to show off your skills and abilities as an agency in the Communications Team of the Year competition.
22nd June 2017
An experimental antibody being developed by Novartis has cut cardiovascular risk in patients who have survived a heart attack in a late-stage study.
22nd June 2017
Santhera Pharmaceuticals’ Raxone has become the first drug for Duchenne Muscular Dystrophy (DMD) to join the UK’s Early Access to Medicines Scheme (EAMS).
22nd June 2017
Shire has finally bagged approval in the US for its long-acting attention deficit hyperactivity disorder drug (ADHD) Mydayis.
22nd June 2017
An experimental therapy being developed by Amgen and Novartis to prevent migraine has been accepted for review in the European Union.
22nd June 2017
